On August 5, 2020 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences (Press release, Harpoon Therapeutics, AUG 5, 2020, View Source [SID1234562942]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 11:30 a.m. ET / 8:30 a.m. PT; and

A "Bispecifics Frontiers: Exploring new biologies and advancing novel therapeutics" panel at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 1 p.m. ET / 10 a.m. PT.
A live audio webcast of the presentation and panel will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.